Novartis(US:NVS) Shang Wu Bu Wang Zhan·2025-08-23 16:53Core Insights - The approval of Coartem Baby, the first malaria treatment specifically formulated for infants, is considered a significant advancement in addressing healthcare disparities for the youngest and most vulnerable populations in Africa [1][2] Group 1: Drug Development and Approval - Coartem Baby is designed for newborns and infants weighing less than five kilograms, developed by Novartis in collaboration with Medicines for Malaria Venture [1] - The Swiss drug regulatory authority approved this formulation in July 2023 [1] Group 2: Impact on Malaria Treatment - The new therapy aims to reduce the risks associated with using adjusted dosages of larger children's medications, which can lead to overdose and toxicity in infants [1] - The approval is seen as a crucial step in combating malaria, ensuring safe and effective treatment for the smallest and most vulnerable infants [1] Group 3: Regional Implementation and Statistics - The drug will be piloted in eight African countries: Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda [2] - The Africa CDC will collaborate with member states to ensure every child has access to treatment [2] - According to WHO, malaria caused 597,000 deaths globally in 2023, with nearly all occurring in Africa, and children under five account for approximately 76% of malaria deaths on the continent [2]